{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 42 of 81', 'Only in patients eligible for PK/QT assessment (all patients assessed as eligible based', 'on the baseline ECG, see Section 9.7.4) - ECG and PK sample should be collected', 'time-matched, first ECG, subsequently PK sample:', '12-lead ECG (to be performed just before the PK sample is taken) to be taken', '1-2 h after study drug intake, exact collection times must be documented)', 'Blood sample for PK 1-2 h after study drug intake (exact collection time must', 'be documented)', '12-lead ECG (to be performed just before the PK sample is taken) to be taken', 'within the time interval of 3-6 h study drug intake (exact collection times must', 'be documented)', 'Blood sample for PK within the time interval of 3-6 h after study drug intake', '(exact collection time must be documented)', 'Schedule Visit 6 for Day 56=3', '9.2.6', 'Visit 6 - Day 56+3 (week 8)', 'Patients need to come for this visit without taking the morning dose of the study drug (this', 'applies only for the study drug. All others medications shall be taken as scheduled)', 'Assessment of NYHA class', 'Concomitant medications (see Section 8.1)', 'Adverse events (see Section 9.6.1)', 'Physical examination', 'Vital signs (BP and pulse rate). See Section 9.7.5.', 'Central lab blood samples for NT-proBNP, hematology, clinical chemistry,', 'coagulation and biomarkers prior to study drug intake (exact collection time to be', 'documented; see Section 9.7.1)', 'Drug accountability, incl. exact time of last dose intake the day before, and collect', 'unused study drug', 'Optional uptitration/sham titration if not yet on target dose, dispense study drug in', 'accordance with dosing regimen for the 6 week interval until Visit 7 and instruct the', 'patient on how to take the study drug.', 'Patient to take the study drug (exact time of intake must be documented)', 'Only in case of uptitration from dose step 3 to dose step 4, 2 h + 15 min after study', 'drug intake: Vital signs BP and pulse rate). See Section 9.7.5.', 'Schedule Visit 7 for Day 84=3', 'Only for patients participating in the optional accelerometry substudy: activity', 'tracking devices are planned to be handed out with instructions to use as specified in', 'the accelerometry procedure manual.']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 43 of 81', '9.2.7', 'Visit 7 - Day 84+3 (week 12)', 'Patients need to come for this visit without taking the morning dose of the study drug (this', 'applies only for the study drug. All others medications shall be taken as scheduled)', 'KCCQ, EQ-5D-5L, PGIC/S (see Section 9.4)', 'Assessment of NYHA class', 'Concomitant medications (see Section 8.1)', 'Adverse events (see Section 9.6.1)', 'Only for patients participating in the optional accelerometry substudy: Activity', 'tracking devices are planned to be collected (see accelerometry manual).', 'Physical examination', 'Vital signs in sitting position (BP and pulse rate). See Section 9.7.5.', '6 MWT', 'Drug accountability, incl. exact time of last dose intake the day before, and collect', 'unused study drug', 'Optional uptitration/sham titration if not yet on target dose, dispense study drug in', 'accordance with dosing regimen for the 6 week interval until Visit 8 and instruct the', 'patient on how to take the study drug.', 'Patient to take the study drug (exact time of intake must be documented)', 'Only in case of uptitration from dose step 3 to dose step 4, 2 h + 15 min after study', 'drug intake: Vital signs (BP and pulse rate). See Section 9.7.5.', 'Schedule Visit 8 for Day 126+3', '9.2.8', 'Visit 8 - Day 126+3 (Week 18)', 'Patients need to come for this visit without taking the morning dose of the study drug (this', 'applies only for the study drug. All others medications shall be taken as scheduled)', 'KCCQ, EQ-5D-5L, PGIC/S (see Section 9.4)', 'Assessment of NYHA class', 'Concomitant medications (see Section 8.1)', 'Adverse events (see Section 9.6.1', 'Physical examination', 'Vital signs in sitting position (BP and pulse rate). See Section 9.7.5', 'Drug accountability, and collect unused study drug.', 'Optional uptitration/sham titration if not yet on target dose, dispense study drug in', 'accordance with dosing regimen for the 6 week interval until Visit 9 and instruct the', 'patient on how to take the study drug.']\n\n###\n\n", "completion": "END"}